STLT - Spotlight Innovation Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.152
-0.002 (-1.299%)
At close: 3:04PM EST
Stock chart is not supported by your current browser
Previous Close0.154
Open0.155
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.131 - 0.155
52 Week Range0.080 - 0.580
Volume12,279
Avg. Volume29,104
Market Cap5.224M
Beta-1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.587
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.65
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Venodol Roll-on, Spotlight Innovation's New Analgesic Product, Now Available at Amazon.com

    URBANDALE, IA, Jan. 11, 2018-- Spotlight Innovation Inc., a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Caretta Therapeutics’ new over-the-counter ...

  • Marketwired5 months ago

    Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product "Venodol"

    Spotlight Innovation Inc. today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing radio and digital media visibility for the Venodol brand ...

  • PR Newswire6 months ago

    Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy

    URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Dr. Androphy is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA. Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Dr. Androphy is a prolific researcher and highly-respected thought leader.

  • PR Newswire6 months ago

    New Chronic Pain Relief Product "Venodol" Now Available for Pre-order at Venodol.com

    URBANDALE, Iowa, Aug. 7, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary Caretta Therapeutics' new over-the-counter chronic pain relief product, Venodol roll-on, is now available for pre-order in the U.S. at venodol.com. Venodol roll-on is a topical analgesic formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and body aches. In the coming months Caretta Therapeutics plans to introduce additional Venodol product formats and to expand distribution to mass merchandise retailers through its Master Broker Agreement with a premier global distribution brokerage firm.

  • PR Newswire7 months ago

    Spotlight Innovation Subsidiary Caretta Therapeutics Engages Public Relations Firm TransMedia Group

    URBANDALE, Iowa, July 11, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has engaged TransMedia Group to provide public relations support for Venodol, a new over-the-counter, non-addictive alternative to opioid and steroidal analgesics that is tentatively scheduled to be available in the United States in summer 2017. "The TransMedia team's proven track record of generating consumer enthusiasm for products in the over-the-counter category makes them highly qualified to manage the product launch and to implement a product awareness strategy for Venodol," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

  • PR Newswire8 months ago

    Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy

    URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company has entered into a Sponsored Research Agreement with Brigham and Women's Hospital (BWH) to support research directed by Kevin Hodgetts, Ph.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Professor Hodgetts is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA.

  • PR Newswire8 months ago

    Spotlight Innovation Engages Investor Relations Firm PCG Advisory Group

    URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has engaged PCG Advisory Group (PCG) to provide investor relations services in support of the Company and its drug development programs, and to strengthen its connection to the investment community. "We are pleased to partner with PCG, a pioneering integrated communications firm, to energize our investor relations activities," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

  • PR Newswire8 months ago

    Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

    URBANDALE, Iowa, June 22, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company will participate in a family-friendly research poster session at the Cure SMA 2017 Annual SMA Conference, which the Company is supporting as a Silver Sponsor. On Friday, June 30, 2017, in the Fantasia Ballroom at Disney's Contemporary Resort in Orlando, FL, Dr. Geoffrey Laff will present a poster entitled STL-182, an Orally-available Small Molecule that Stabilizes SMN Protein. "We are proud to be a sponsor of this year's Cure SMA Annual SMA Conference and to present a poster designed to help families directly affected by SMA gain a better understanding of the disease," said Dr. Laff, Spotlight Innovation's Senior Vice President of Business Development.

  • PR Newswire8 months ago

    Spotlight Innovation Inc. Issues Statement About Recent Stock Trading Activity

    URBANDALE, Iowa, June 21, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that on June 15, 2017, it was made aware by OTC Markets of promotional activities surrounding the Company's common stock. According to the OTC Markets the activities were promotional newsletter emails encouraging investors to purchase the Company's common stock and this promotional activity coincided with higher than average trading volume and fluctuations in the Company's stock price.

  • PR Newswire8 months ago

    Spotlight Innovation Subsidiary Caretta Therapeutics Signs Second Venodol API Production Agreement

    URBANDALE, Iowa, June 14, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has signed a manufacturing agreement with Orlando, FL-based contract manufacturing organization (CMO) Maitland Labs, LLC, for the production of the active pharmaceutical ingredient (API) for Venodol, the Company's first over-the-counter product for the treatment of chronic pain. Maitland Labs is the second CMO producing Venodol's API on behalf of Caretta Therapeutics.

  • PR Newswire8 months ago

    Spotlight Innovation Former CEO Returning Additional 1.6 Million Shares to Company Treasury

    URBANDALE, Iowa, June 8, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that former Chief Executive Officer Cristopher Grunewald has agreed to return 1,618,627 shares of common stock to the Company treasury. The shares being returned are in addition to the prior return by Mr. Grunewald of 1,000,000 shares of common stock to the Company treasury in the first quarter of 2017. Concurrent with the May 2017 stock surrender agreement, Mr. Grunewald entered into a consulting agreement which provided for Mr. Grunewald to be engaged as a consultant to the Company for two years and to receive a warrant to purchase up to 500,000 shares of common stock at an exercise price of $1.25 per share for a term of three years.

  • PR Newswire9 months ago

    Spotlight Innovation Subsidiary Caretta Therapeutics Begins the Manufacturing Process for Venodol, a New Over-the-Counter Product to Treat Chronic Pain

    URBANDALE, Iowa, May 31, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that subsidiary Caretta Therapeutics, LLC, has begun the process of manufacturing Venodol topical roll-on, a non-addictive alternative to opioid and steroidal analgesics intended to provide relief from chronic pain. The manufacturing of Venodol is taking place at contract manufacturing organization (CMO) facilities located in Florida in the United States. Commenting on the start of the manufacturing process, John Krohn, Spotlight Innovation's President and Chief Executive Officer, said, "Commencing production is an exciting milestone in our efforts to bring Venodol to the commercial market.

  • PR Newswire9 months ago

    Spotlight Innovation Appoints Dr. June Beetler to Board of Directors

    URBANDALE, Iowa, May 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that June Beetler, D.O., has been appointed to the Company's Board of Directors. Dr. Beetler joins current board members John M. Krohn, Craig A. Lang, Dr. Sanjeev Agarwal, and Ralph Arthur. "Dr. Beetler has expansive medical knowledge and hands-on patient care experience, and we are delighted to have such an outstanding practitioner join us," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

  • PR Newswire9 months ago

    Spotlight Innovation Appoints John Krohn Interim Chief Executive Officer

    URBANDALE, Iowa, May 23, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company's Board of Directors has accepted the resignation of Cristopher Grunewald as Chief Executive Officer (CEO) and appointed John M. Krohn as interim CEO, effective immediately. Mr. Krohn will continue to serve as Chairman of the Board, President and Chief Operating Officer.

  • PR Newswire11 months ago

    Spotlight Innovation Commences Part 2 of Phase I Cancer Trial

    URBANDALE, Iowa, March 10, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that its subsidiary Celtic Biotech has begun Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd., a company specializing in clinical development, is the contract research organization (CRO) overseeing the study conduct. Dr. Gil-Delgado is a member of the American Society of Clinical Oncology (ASCO).

  • PR Newswire11 months ago

    Spotlight Innovation to Present at 29th Annual ROTH Conference on March 15, 2017

    URBANDALE, Iowa, March 7, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company management ...